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The presence or absence of steroid hormone receptors in normal human breast tissue and breast cancers has helped to direct treatment protocols for many years (1) (2) (3) (4) . Presumably, patients with tumors containing sufficient amounts of steroid receptor should respond favorably to hormonal therapy. In breast-cancer patients, however, up to 40% of those patients with tumors containing estrogen receptor fail to respond to therapy with anti-estrogens (5,6). The identificationofnonfunctional steroid receptors in target tissues that are able to bind theirrespective steroidbut are unable to bind nuclear-acceptor sites and alter gene transcription has been reported in many steroid-receptor model systems (7 -13) . The existence of these nonfunctional receptors may correlate with those breast carcinoma biopsies that are shown to contain estrogen receptors by the dextran-coated charcoal assay (DCC assay), but that fail to respond to endocrine therapy (8,13).Indeed, the measurement of other indicators of estrogen-receptor function, such as the concentrations of progesterone receptor (14) or concentrations of nuclear-bound progesterone receptor (8, 9, 13), has been used to attempt to improve the ability to predict a steroid response.
We recently developed a nuclear binding assay to assess the biological activity of steroid receptors in cells isolated from animal and human tissues (15) . The assay is capable of estimating the number of receptor molecules in intact cells that can be activated and bound to nuclear-acceptor sites. Although the nuclear binding assay proved to be reproduc-ible and reliable for use in human benign tissues and carcinomas, its use was limited by the requirement of relatively large tissue specimens for a reliable assay (a minimum of 0.5 g for breast carcinomas), and its relatively labor-intensive nature. Here we describe a modifiedassay, which is simpler, more sensitive, and requires less tissue than the original nuclear binding assay. We have used the chicken oviduct model system to examine the limits and specificity of the assay, as was done in the original assay (15) , because the receptors in this system are well documented (10, 11, 16) . Biopsies from breast-carcinoma patients were assayed both by the micro biopsy nuclear binding assay (BNB assay) and by the DCC assay and the results compared. For comparisons of values, reproducibility, and feasibility of these studies, we used two sensitive DNA quantification methods.
Materials and Methods

Isotopes and Reagents
Radioactive R5020 ([17a-methyl-3Hlpromegestone, spec. acty. 87 kCilmol) and [2,4,6,7-3H]estradiol (spec. acty. 97.8 kCilmol) were obtained from New England Nuclear, Boston, MA; "Phase Combining System" scintillation fluid was from Amersham Co., Arlington Heights, IL; Ready-Solv HP/b, was from Beckman Instruments, Fullerton, CA; ethidium bromide, calf thymus DNA, and pronase/protease (Streptococcus grz.seus)were from Calbiochem, La Jolla, CA; collagenase (Type ifi) was from Cooper Biomedical, Malvern, PA; acetaldehyde was from Eastman Kodak Co., Rochester, NY; diethylstilbestrol, bovine serum albumin, and reagentgrade chemicals were from Sigma Chemical Co., St. Louis, MO; glacial acetic acid and diphenylamine were from J. T. Baker Chemical Co., Phillipsburg, NJ; and MCDB-202 culture medium was from Irvine Scientific, Santa Ana, CA.
Tissue Sources
Seven-day-old White Leghorn chickens were each injected daily with 5 mg of diethyistilbestrol in sesame oil for 18 to 28 days to stimulate oviduct growth (16,17).They were then killed and tissue was removed. Both oviduct and pancreas were used immediately for nuclear binding assays. Waste material from fresh surgical breast-carcinoma biopsies was obtained from patients treated at the Mayo Clinic from March 1987 through May 1987. Tissue for the nuclear binding assay was taken from regions adjacent to and as similar as possible to that used for histopathological evaluation and for steroid-receptor measurement by the DCC assay. On pathological examination, the breast-carcinoma biopsies were Grade 2, 3, or 4 adenocarcinomas. Specimens for analysis of functional steroid receptors (i.e., of nuclear binding) were not sorted by age or metastatic status of the patients. For transport to the laboratory, tissue samples for nuclear binding assays were placed at 4#{176}C in MCDB-202 medium containing 40 g of bovine serum albumin per liter; tissue processing was usually begun within 2 h of surgical removal. Control experiments confirmed that storage at 4 #{176}C for no more than 24 h resulted in no measurable loss of specific nuclear binding. Surgical specimens for the DCC assay of total receptor content were stored at -80 #{176}C for no more than five days before analysis.
Procedures
The biopsy nuclear binding assay. This assay, in general, has been described previously (15 To enhance the cell dispersion, we mixed the suspension by pipetting it up and down at 15-nun intervals, then filtered the suspension through nylon mesh and added to the filtrate an equal volume of the albumin-containing MCDB-202 medium to inactivate the collagenase. The remaining undigested tissue was suspended in a fresh solution of collagenase. The digestion, pipetting, and ifitration of the undigested sections were repeated as above and the pooled filtrates ("digested tissue") were centrifuged for 5 mm at 1000 x g at 22 #{176}C. The cell pellets were suspended in 5 mL of MCDB-202 medium and centrifuged twice more. Care was taken to first suspend the cell pellets in a small volume (0.1 mL) to minimize aggregation. We then suspended the final pellets in an appropriate volume of media for radioligand binding and assessedthe integrity of the cell membranes by dye exclusion with trypan blue (15). Undisrupted cells usually exceeded 90% of the total population. For ligandbinding studies, we diluted the cell suspensions so that 0.1-mL aliquots contained 1 to 10 pg of DNA.
For estimation of nonspecific and total nuclear binding, we evaporated preparations of radioactive promegestone, a synthetic progestin (R5020), in 15-mL tubes or 1.5-mL microcentrifuge tubes at 37 #{176}C to yield 10 nmollL when resuspended, unless otherwise indicated in the text, with or without a 100-fold excess of unlabeled R5020, respectively. We then added 0.1 or 0. These conditions were previouslyfound to be optimal for isolating nuclei with bound "activated" receptors while removing "unactivated" receptors (15). In analyses for DNA by the fluorescence method, we resuspended each nuclear pellet in 1.1 mL of an ice-cold mixture (pH 7.4) containing, per liter, 50 mmol of Tris and 100 mL ofglycerol. Previously described methods for DNA estimation with ethidium bromide (18, 19) were optimized for pH, pronase concentration, and time of pronase digestion, for use with nuclei from collagenase-digested tissues. Pronase, a mixture of several proteolytic enzymes, was added to each tube to give a final concentration of 12.5 P.U.K. units per milliliter, unless otherwise indicated [1 proteinase activity unitofKaken (P.U.K.)isdefined as the activity ofenzyme that liberates a digestion product equivalent to 25 pg of tyrosine at 40 #{176}C, pH 7.5 (Kaken Chemical Co., Ltd., Tokyo, Japan)]. Samples were vortex-mixed, covered, and incubated for 1 h in a 37 #{176}C water bath, then centrifuged (4#{176}C, 15 mm, 5000 x g). We removed 1 mL of the supernateforDNA quantification with ethidium bromide, adding ethidium bromide from a stock solution (0.2 g/L in distilled water) to each assay tube to give a final concentration of 2.5 mg/mL. After vortex-mixingthe contents of the tubes, we promptly measured the relative fluorescence in an Aminco-Bowman spectrophotofluorometer (American Instrument Co., Silver Spring, MD), using an excitation wavelength of 520 nm and an emission wavelength of 590 nm. The DNA concentrationin each assay tube was then calculated by using a standardcurve based on results with calf thymus DNA treated similarly. For radioactivity determination, expressed in disintegrationsperminute (DPMs), we transferred 1-mL aliquots from each assay tube to a scintillation vial and added 10 mL of scintillation fluid ("Phase Combining System"/xylene, 2/1 by vol), reading results in a LS2800 liquid scintillation counter (Beckman Instruments, Fullerton, CA) with an efficiency of 45%.
Isolation of nuclei for DNA quantitation by a micro version of the diphenylamine assay. In the experiments involving the micro version of the diphenylamine assay of Burton for DNA estimation(20), we suspendedthe cell pellets in 1 mL of Buffer A (no sucrose) and homogenized them as above. We then layeredthe homogenate over 0.5mL ofsucrose/Buffer A, as above,and centrifuged (10mm, 5000 X g,4 #{176}C). Again, there was no contamination of the purifiednucleiwith cytoplasm.After resuspending each nuclear pellet in 1 mL of Buffer A and centrifuging (10 mm, 5000 x g), we extracted the radioactivity from each sample by adding 1 mL of a 0.25 mollL solution of sodium acetatein absolute ethanol, mixing the contents of each tube on a rocking platform for 1 h, and centrifuging (5 mm, 2000 X g). We then added 10 mL of Ready-Solv HP/b scintillation fluid to theethanolsupernates and countedthe radioactivity in the liquid scintillation counter.
The residualnuclearpellets from the assay tubesand the DNA standard tubes were then treated for spectrophotometric estimation of DNA by a modification to a microversion of theBurton procedure (20) . Briefly, all tubes were heated (15 mm, 90#{176}C) in 0.1mL of0.5molIL perchloric acid; then we added 0.2 mL of diphenylamine solution [15 g of diphenylamine, 5 mL of acetaldehyde stock (20 mL of acetaldehyde per liter in distilled water stored at 4#{176}C), and 1 L of sulfuric acid stock(15 mL of sulfuric acid per liter in glacial acetic acid stored at room temperature)1 and briefly mixed the contents of each tube before leaving them in the dark at room temperature overnight. The next day we measured the absorption at 600 nm of 0.2 mL of the clearsupernatein round-bottom microtiter plates, using a MR 600 Microplate Reader (Dynatech, Torrance, CA). The DNA concentration was then calculated by comparison with a standard curve based on calf thymus DNA treated similarly.
Calculations. For each assaytube, divide the disintegrations per minute by the corresponding DNA value in micrograms. To obtain specific binding,subtractthe mean 
Results
Effect of Tissue Quantity
DNA recovery in the BNB assay. We assessed DNA recovery in the nuclear binding assay in oviduct tissue, using both the fluorescence and diphenylamine methods. Procedures. The cell suspensionwasthendiluted with MCDB-202 media and aliquoted such that the assay tUbeS contained 100 to 6.5 mg of tissue equivalents.The contents ofthetubes were labeled with[3H]R5020, 10 nmol/L, with or without a 100-fold excess of unlabeledR5020, and processedas described inProcedures for assayofnuclear binding. The DNA wasquantifiedby the microdiphenylamine procedure. Each point represents themean ± SD for quadruplicateassaysatthe measured DNA concentrations 
Tissue and Steroid Specificities of the Assay in Avian and
Human Tissues
To verif& that the nuclear binding in this assay is steroid specific, we incubated oviduct cell suspensions for 1 h with 10 nmol of [3H]R5020 per liter, alone or with a 100-fold excess of unlabeled diethyistilbestrol, R5020, or cortisol. We isolated nucleias described above,then measured the DNA and nuclear-bound radioactivity per tube. As shown in Figure 4 , only unlabeled R5020 competed for [3H1R5020 binding, thus demonstrating a steroid specificity with respect to the nuclear binding. Figure 5 shows a similar steroid specificity for this assay for specific estrogen-receptor bindingin a breast-carcinoma biopsyspecimen.Aliquotsof To determine saturation of nuclear binding for the estrogen receptor in human breast carcinomas, we incubated aliquots of a suspension of breast-cancer cells with increasing concentrations of [3H]estradiol, with or without a 100-fold excess of unlabeled diethylstilbestrol.
As shown in Figure 7 , the nuclear binding was saturated at approximately 10 nmol of [3H]estradiol per liter.
Assay Correlations in Breast Carcinomas
Resultsfortotal unoccupied estradiol receptor in cytosol as measured by the standard assay (DCC assay) were compared with determinations of functional estrogenreceptor (by the micro BNB assay) in selected human breast carcinomas. A lower limit of 1000 moleculesper cell nucleus was considered a positive indicator for steroid response, based on previousanalysesofthe avian oviduct progesterone and estrogen systems (15,24,25) ;
in the DCC assay, we used a lower limit of 3 fmol of estrogen receptor per milligram of cytosol protein (25) . By these criteria, eight of 12 breast cancer biopsies assayed had equivalent results by both methods (Figure 8 ). Of the remaining four patients, three were DCC assay-positive and BNB assay-negative (indicative of nonfunctional receptors) and one was DCCnegative and BNB-positive. Given that 10-15% of those patients who are estrogen-receptor-negative by the DCC assay do respond to hormonal therapy, and that an even greater number who are estrogen-receptor-positive by the DCC assay do not respond to steroid therapy, the BNB assay may be able better to distinguish between those patients who will and those who will not respond to steroid treatment.
Discussion
This micro BNB assay,developedto assessthe biological activity of steroid receptors in small samples (e.g., needle biopsies)of target tissues, quantifies the functional receptors, that is, the steroidreceptors that can be activated and bind to acceptor siteson the nucleus.A modification of a previouslydeveloped assay (15) , this micro BNB assay For quantifying DNA in the micro BNB assay,the micro diphenylamine assay is simpler and lesstime consuming than the ethidium bromide method. We have found that the micro BNB assaycan be appliedtoany tissue forany steroid system over a wide range of tissuequantities. In avian tissues, thenuclearbindingofa synthetic progestin, R5020, as assessedwith this micro BNB assay, was saturable and steroid-specific; likewise, the nuclear binding of estradiol in human breast cancer tissue was steroid specific and saturable.
This assay is designed not only to detect the presence of steroid receptors, but also to determine whether they are biologically active. Combined with the DCC assay, the BNB assay can identify functional and nonfunctional steroid receptors in human tissues. Steroid receptors are known to undergo changes in both concentration and function in target cells. Progesterone receptors in chicken oviduct exhibit seasonal variation in their concentrations and capacities to become activated and bind to nuclear acceptor sites (10, 27) . Progesterone receptors display changes in concentrations and in biological activityin response to estradiol and progesterone (16, 28, 29) and have decreased biological activity in aged, nonlaying hens or in chickens withdrawn from diethyistilbestrol stimulation (11, 16, 29,  30) . Defects in the nuclear binding of estradiol, with evidence of nonfunctional estrogen receptors, have been demonstrated in human breast cancer (8, 13). Further, nonfunctional androgen receptors have been described in the instance of androgen insensitivity (7) . capabilities (8, 13, 14,35) . Two groups (8, 13) found a very low response rate to endocrine therapy in patients with defective nuclear uptake of estrogen receptors. Here we used the micro BNB assay to identify nonfunctional receptors ina few selected breastcarcinomas.
Comparing theDCC assay results with theestrogennuclear bindingresults for12 specimens, we found that three of the specimens were positive by the DCC assay (greater than 3 finolimg protein) and negative by the BNB assay (less than 1000 molecules per cell nucleus); that is, they possessed nonfunctional receptors. Although the minimal number of molecules per cell necessary for response to hormonal manipulation in breast cancer is undetermined at this time, several groups have shown that 600-1000 molecules per cell nucleus are required for the induction of RNA polymerase II or egg-white gene expression in the avian oviduct (15, 24, 25). Validation of a lower limit for positivity in the BNB assay in human tissues should arise as we correlate the positive responses to hormonal therapy for a larger number of patients. Studies are underway in this laboratory to address this issue, and to assessthe predictive accuracy of this assay for steroid responses in human breast tissues.
